Sauter Edward R, Qin Wenyi, Schlatter Lisa, Hewett John E, Flynn John T
Surgery, University of Missouri, Columbia, MO 65212, USA.
BMC Cancer. 2006 Oct 18;6:248. doi: 10.1186/1471-2407-6-248.
Celecoxib inhibits PGE2 production in cancerous tissue. We previously reported that PGE2 levels in nipple aspirate fluid (NAF) and plasma were not decreased in women at increased breast cancer risk who received celecoxib 200 mg twice daily (bid). The endpoints of the current study were to determine if a short course of celecoxib 400 mg bid would decrease PGE2 levels in women 1) at increased breast cancer risk, and 2) with established breast cancer.
NAF and plasma samples were collected before, 2 weeks after taking celecoxib 400 mg bid, and two weeks after washout from 26 women who were at increased breast cancer risk. From 13 women with newly diagnosed breast cancer, NAF from the incident breast and plasma were collected before and on average 2 weeks after taking celecoxib. Additionally, in nine of the 13 women with breast cancer, NAF was collected from the contralateral breast.
No consistent change in NAF or plasma PGE2 levels was noted in high risk premenopausal women. NAF PGE2 levels decreased after celecoxib administration in postmenopausal high risk women (p = 0.02), and in both the NAF (p = 0.02) and plasma (p = 0.03) of women with breast cancer.
Celecoxib 400 mg bid taken on average for 2 weeks significantly decreased NAF, but not plasma, PGE2 levels in postmenopausal high risk women, and decreased both NAF and plasma PGE2 levels in women with newly diagnosed breast cancer. PGE2 levels may predict celecoxib breast cancer prevention and treatment efficacy. Our observations are preliminary, and larger studies to confirm and extend these findings are warranted.
塞来昔布可抑制癌组织中前列腺素E2（PGE2）的生成。我们之前报道过，对于乳腺癌风险增加的女性，每日两次服用200毫克塞来昔布后，乳头抽吸液（NAF）和血浆中的PGE2水平并未降低。本研究的目的是确定短期每日两次服用400毫克塞来昔布是否会降低以下两类女性的PGE2水平：1）乳腺癌风险增加的女性；2）已确诊乳腺癌的女性。
收集了26名乳腺癌风险增加女性在服用每日两次400毫克塞来昔布前、服药2周后以及停药2周后的NAF和血浆样本。从13名新诊断为乳腺癌的女性中，收集了患侧乳房的NAF和血浆样本，分别在服用塞来昔布前和平均服药2周后采集。此外，在这13名乳腺癌女性中的9名，还收集了对侧乳房的NAF。
绝经前高危女性的NAF或血浆PGE2水平未出现一致变化。绝经后高危女性服用塞来昔布后，NAF中的PGE2水平降低（p = 0.02），乳腺癌女性的NAF（p = 0.02）和血浆（p = 0.03）中的PGE2水平均降低。
平均服用2周的每日两次400毫克塞来昔布可显著降低绝经后高危女性NAF中的PGE2水平，但对血浆PGE2水平无影响，且可降低新诊断乳腺癌女性的NAF和血浆PGE2水平。PGE2水平可能预测塞来昔布对乳腺癌的预防和治疗效果。我们的观察结果是初步的，需要更大规模的研究来证实和扩展这些发现。
